Drug Profile
F 652
Alternative Names: F-652; IL-22 IgG2 Fusion Protein; IL-22 IgG2-Fc; P-652; Recombinant Human Interleukin-22 IgG2-Fc; rhIL-22 dimerLatest Information Update: 09 Oct 2023
Price :
$50
*
At a glance
- Originator Generon (Shanghai) Corporation
- Developer Evive Biotech
- Class Anti-inflammatories; Antivirals; Hepatoprotectants; Immunoglobulin Fc fragments; Interleukins; Recombinant fusion proteins
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Alcoholic hepatitis; COVID 2019 infections; Graft-versus-host disease
- No development reported Pancreatitis
Most Recent Events
- 02 Oct 2023 Evive Biotech withdraws a phase II trial prior to enrolment for COVID-2019 pneumonia (IV), due to compound development plan changed (NCT05205668)
- 28 Sep 2023 No recent reports of development identified for phase-I development in Pancreatitis in China (Parenteral)
- 28 Sep 2022 Discontinued - Phase-II for Alcoholic hepatitis in China (Parenteral) (Yifan pipeline, September 2022)